Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

4.54
+0.19004.37%
Post-market: 4.600.0600+1.32%19:05 EDT
Volume:23.27K
Turnover:105.38K
Market Cap:7.41M
PE:-0.24
High:4.80
Open:4.42
Low:4.40
Close:4.35
52wk High:71.50
52wk Low:3.18
Shares:1.63M
Float Shares:1.22M
Volume Ratio:0.95
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:2.32
PE(LYR):-0.08

Loading ...

Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement

Reuters
·
Aug 28

Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation

Reuters
·
Aug 27

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Dow Jones
·
Aug 10

Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview

Reuters
·
Aug 08

Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue

Reuters
·
Aug 07

Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors

Reuters
·
Jul 24

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

GlobeNewswire
·
Jul 24

NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am

Reuters
·
Jul 15

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
Jul 15

Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study

Reuters
·
Jul 15

Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026

THOMSON REUTERS
·
Jul 14

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

GlobeNewswire
·
Jul 14

Ernexa Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 03

Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3

Reuters
·
Jun 27

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

GlobeNewswire
·
Jun 25

Ernexa expects FDA review of ERNA-101 IND in Q4 2026

Reuters
·
Jun 17

Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026

THOMSON REUTERS
·
Jun 17